The goal of this clinical trial is to learn whether Nicotinamide adenine dinucleotide (NAD+) can influence cognition and biomarkers in healthy, cognitively intact women aged 40-80. The main questions it aims to answer are: Will cognitive functioning change in response to NAD+? Will inflammatory markers and serum indicators of neurodegeneration change in response to NAD+? Researchers will compare individuals receiving NAD+ to those receiving placebo to see if the results differ. Participants will: Complete an online questionnaire, Visit the lab for computerized cognitive testing and a blood draw, Take NAD+ or a placebo every day for 4 weeks, Visit the lab for computerized cognitive testing and a blood draw
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
53
Participants will take a supplement for four weeks. The supplement will either be Nicotinamide adenine dinucleotide or a placebo.
Participants will take a supplement for four weeks. The supplement will either be Nicotinamide adenine dinucleotide or a placebo pill.
University of Rhode Island
Kingston, Rhode Island, United States
Independence Square, University of Rhode Island
Pawtucket, Rhode Island, United States
Neurocognition
NIH Toolkit Cognition Battery, Automated Neuropsychological Assessment Metrics
Time frame: four weeks
Neurodegenerative disease panel
BDNF, Cathespin D, MPO, PAI-1 (total), PDGF-AA, PDGF-AB/BB, RANTES, slCAM-1, sNCAM, sVCAM-1
Time frame: four weeks
Markers of systemic inflammation
GM-CSF, IFNγ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-13, IL-17A, IL-23, TNFα
Time frame: four weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.